Albireo announces presentation of new data in pediatric and adult liver diseases

Boston, june 23, 2022 (globe newswire) -- albireo pharma, inc. (nasdaq: albo), a rare liver disease company developing novel bile acid modulators, today announced the presentation of new data in pediatric and adult liver diseases at the european association for the study of the liver (easl) international liver congress™ 2022 being held in london. the presentations provide new analyses of the phase 3 pedfic 1 and pedfic 2 trials of bylvay® (odevixibat) in progressive familial intrahepatic cholestasis (pfic), as well as data on pipeline asbt/ntcp inhibitor compounds, including a2342 in hepatitis b and d.
ALBO Ratings Summary
ALBO Quant Ranking